Compare GE Aerospace (GE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Organon & Co. Common Stock — how do they compare? GE Aerospace trades at $308 (market cap $319.19B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: GE Aerospace is far larger — about 88.2× Organon & Co. Common Stock's market cap, and GE Aerospace pays the higher dividend (0.61%). Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Organon & Co. Common Stock for 0 Days on average.
| GE | OGN | |
|---|---|---|
Market Cap | $319.19B | $3.62B |
Volume | 4,516,693 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $381.22 | $13.81 |
52-Week Low | $273.25 | $5.70 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $329.00B | $11.04B |
Dividend Yield | 0.61% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $308.64, showing modest daily gains of 0.14% amid mixed technical signals. The stock maintains strong fundamentals with three consecutive quarterly earnings beats, robust 48.79% ROE, and improving profit margins reaching 18.98% in 2025. Recent news highlights the company's $12 billion CPP acquisition to strengthen its aerospace supply chain capabilities while maintaining shareholder returns through dividends and buybacks.
Outlook remains positive with analyst consensus at $409.60 price target (32.7% upside) and no sell ratings. Key opportunities include aerospace demand growth and strategic acquisitions, while risks involve high valuation multiples (P/E 36.28) and integration challenges from recent M&A activity. The bearish technical picture suggests potential near-term consolidation before fundamental strengths drive long-term appreciation.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
